Our research interests focus on the study of the transcriptional and epigenetic mechanisms dysregulated in metabolic disorders such as Insulin Resistance (IR) and Type II Diabetes Mellitus (T2DM). Our team relies on the use of the innovative reprogramming technique to derive induced pluripotent stem cells (iPSCs) from fibroblasts obtained from large cohorts of patients and healthy donors. iPSCs can be differentiated to virtually all cell types of the human body and therefore constitute an unprecedented cellular platform to model disease progression. 
Our team combines reprogramming, next generation sequencing (NGS), genome editing and cellular biology techniques to identify the transcriptional and epigenetic signatures prognostic of metabolic diseases and to develop in vitro screening assays aimed to isolate chemical compounds able to revert these pathological signatures.​

Latest News

08 November, 2019

CRG Grant Awarded to STEMD Lab

Congratulations to Professor Adamo and STEMD Lab members on the receipt of the CRG Grant

Read more

12 May, 2020

KAUST Smart Health Initiative Seed Grant Awarded to STEMD Lab

Professor Adamo and his team have been awarded the KAUST Smart Health Initiative Seed Grant for their project entitled “An iPSC-based disease-modeling approach to study Klinefelter Syndrome in a unique cohort of Saudi patients”. This project will be executed in collaboration with a scientific team from King Abdulaziz University (KAU) in Jeddah.

Read more

23 April, 2020

MSc Student Dalal Al-Farhan successfully defends her MSc Thesis

Congratulations to Dalal Al-Farhan on the successful defence of her MSc thesis entitled "Dissecting the Role of the Histone Demethylase KDM1B in Maintenance of Pluripotency and Differentiation of Human Embryonic Stem Cells". Dalal is the second masters student to graduate from Professor Adamo's group.

Read more